DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata Et Al US 2011 O15893 OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata et al. (43) Pub. Date: Jun. 30, 2011 (54) METHOD FOR TREATMENT OF RRTABLE Related U.S. Application Data BOWEL, SYNDROME (60) Provisional application No. 61/190.559, filed on Aug. 28, 2008. (75) Inventors: Takuya Hirata, Tokyo (JP); Toshiyuki Funatsu, Tokyo (JP); Publication Classification Yoshihiro Keto, Tokyo (JP); (51) Int. Cl. Shinobu Akuzawa, Tokyo (JP) A63L/78 (2006.01) C07D 403/06 (2006.01) (73) Assignee: ASTELLAS PHARMA INC., A6IPI/00 (2006.01) Tokyo (JP) A6IPL/T2 (2006.01) (52) U.S. Cl. ................................... 424/78.01: 548/302.7 (21) Appl. No.: 13/061,384 (57) ABSTRACT A method for treatment of a patient suffering from irritable (22) PCT Fled: Aug. 27, 2009 bowel syndrome with diarrhea or mixed irritable bowel syn drome, which comprises administering to the patient a thera (86) PCT NO.: PCT/UP2009/064904 peutically effective amount of ramosetron or a pharmaceuti cally acceptable salt thereof in combination with a S371 (c)(1), therapeutically effective amount of polycarbophil or a phar (2), (4) Date: Feb. 28, 2011 maceutically acceptable salt thereof. Patent Application Publication Jun. 30, 2011 Sheet 1 of 2 US 2011/O1589.30 A1 Fig.1 s 120 aw *e 100 aS$ 100 80 isd 80 v s 60 se sk sk 60 40 6 40 se g 20 20 - a k es O -- - - - , , , g- O W 0. 0.3 1 100 300 000 0.3 g/kg 300 mg/kg 0.3 g/kg + s S. 300 mg/kg Ramosetron Polycarbophi s Š w gkg) (mg/kg) s? s S s cSSk 2 s SS ; SS {r q'sS. & Fig.2 A B it; 120 s 100 s s OO 80 80 - 60 60 3 40 ce: 40 20 is 20 ra r 0 8.- 2 0 OW 1. 3. 100 100 300 OO W 30 g/kg 300 mg/kg 30 g/kg + r--------------------- KY S. 300 mg/kg Ramosetron Polycarbophil s S gkg) (mg/kg) ass g s S. c S. k q'ss & Fig. 3 6 250 5 200 g sk ss 150 - 3 100 – 50 H O OW 10 30 OO 100 30 OOO Ramosetron Polycarbophil (ug/kg) (mg/kg) Patent Application Publication Jun. 30, 2011 Sheet 2 of 2 US 2011/O1589.30 A1 Fig.4 250 2OO 150 1OO 50 O ---- DW 3OO 1000 DW 300 1000 Polycarbophil Polycarbophil (mg/kg) (mg/kg) Ramosetron 100 g/kg Fig.5 250 200 - 150 100 50 OW 3OO 1000 DW 3OO 1000 Polycarbophil Polycarbophil (mg/kg) (mg/kg) Ramosetron 100 uglkg US 2011/0158930 A1 Jun. 30, 2011 METHOD FOR TREATMENT OF RRTABLE 0007 Patent Reference 3: U.S. Pat. No. 3,297,664 BOWEL, SYNDROME 0008 Patent Reference 4: WO 2004/062623 TECHNICAL FIELD 0009 Patent Reference 5: WO 2008/096777 0001. The present invention relates to a treatment method of using ramosetron or a pharmaceutically acceptable salt Non-Patent References thereof in combination with polycarbophil or a pharmaceuti (0010. Non-Patent Reference 1: Gastroenterology, 2006; cally acceptable salt thereof for treatment of a patient suffer 130: p. 1480-1491 ing from irritable bowel syndrome with diarrhea or mixed 0011 Non-Patent Reference 2: Japanese Journal of Phar irritable bowel syndrome. macology, 2002; 89: p. 133-141 BACKGROUND ART 0012 Non-Patent Reference 3: Neurogastroenterology 0002 Irritable bowel syndrome (IBS) is a functional gas and Motility, 2008; 20(5): p. 557-565 trointestinal disorder with which the patient experiences chronic disturbance of bowel habit (constipation or diarrhea) DISCLOSURE OF THE INVENTION and abdominal pain/discomfort without any organic disease 0013 The present inventors have assiduously studied for in the gastrointestinal tract. According to the diagnostic cri the purpose of creating a more excellent treatment method for teria for IBS (Rome III Criteria) published in 2006, IBS is patients suffering from IBS with diarrhea or mixed IBS. categorized as IBS with constipation, IBS with diarrhea, 0014. As a result, the inventors have confirmed an excel mixed IBS or unclassified IBS (for example, see Non-Patent lent synergistic effect of ramosetron in combined administra Reference 1). It is reported that the prevalence of IBS to the tion with polycarbophil both in the pharmacological efficacy total population reaches 10% to 20% and IBS patients and the side effect thereof, and have completed the present account for about 20 to 40% of outpatients in gastrointestinal invention. medicine department, and it is considered that IBS is a gas 0015 Using a restraint stress induced rat diarrheal model trointestinal disorder recognized at high frequency. Further, and a 5-HT induced mouse diarrheal model, the inventors the IBS symptom greatly worsens the quality of life and the investigated the Synergistic effect of ramosetron and polycar work productivity of the patient, which is being a serious bophiland have found that the combined use of the two drugs Social problem. At present, for the pharmacological treatment significantly enhances the respective inhibitory effects for of IBS, mainly used is an antispastic drug Such as anticholin diarrhea. Further, the inventors have found that the repeated ergic drug, an antidiarrheal drug such as opioid receptorago combined administration of ramosetron and polycarbophil nist, or a bulking-agent or a probiotics for regulating the attenuates the inhibitory effect of ramosetron on spontaneous enteric environment. defecation in mice. On the other hand, it is reported that a 0003 Ramosetron is a serotonin (5-HT) receptor antago high-molecular polymer Such as colestimide or sevelamer nist having a chemical name of (-)-(R)-5-(1-methyl-1H hydrochloride adsorbs the other low-molecular compound indol-3-yl)carbonyl-4,5,6,7-tetrahydro-1H-benzimidazole administered simultaneously therewith and attenuates the (for example, see Patent Reference 1). Heretofore, ramo absorption and the effect of the compound (Kayset al., Am. J. setron has been prescribed for an adult patient with the gas Kidney Dis. 2003:42: 1253-1259;Yamada et al., Pharmacol trointestinal symptom Such as vomiting caused by antine ogy and Therapy, 2001; 29: 37–44). However, oral adminis oplastic agents, in a mode of oral administration at a dose of tration of a prepared mixed solution of ramosetron and poly 0.1 mg once a day or intravenous injection at a dose of 0.3 mg carbophil has been confirmed to possess the antidiarrheal once a day. Recently, it has been confirmed that ramosetron effect, but on the contrary, rather provides significant effect hydrochloride at an extremely low daily dose of 0.001 to 0.05 enhancement; and therefore, it is considered that the possi mg is also effective for treatment of IBS with diarrhea (for bility that polycarbophil may adsorb ramosetron to attenuate example, see Patent Reference 2). At present, there are only a the effect thereof would be low. few reports showing the efficacy of the combined use of 5-HT, receptor antagonist with any other agent for IBS, such SUMMARY OF THE INVENTION as a noradrenaline reuptake inhibitor and a mast-cell degranu lation inhibitor (for example, see Patent References 4 and 5), 0016 Specifically, the invention relates to the following: while it is still unclear whether the concomitant administra 0017 (1) A method for treatment of a patient suffering tion of ramosetron with the existing agents for IBS described from irritable bowel syndrome with diarrhea or mixed irri above show the beneficial synergistic effect. table bowel syndrome, which comprises administering to the 0004. On the other hand, polycarbophil is a polyacrylic patient a therapeutically effective amount of ramosetron or a acid crosslinked with divinylglycol, and is a high-molecular pharmaceutically acceptable salt thereof in combination with polymer having high water absorbability (for example, see atherapeutically effective amount of polycarbophil or a phar Patent Reference 3). Polycarbophil is used as an antidiarrheal maceutically acceptable salt thereof; drug or for treatment of altered bowel habit in IBS. Specifi 0018 (2 The method of 1 comprising administering to cally, it is considered that, owing to its water absorbing effect, the patient 0.001 to 0.05 mg of ramosetron hydrochloride as polycarbophil could absorb water in an intestinal lumen a daily dose or an equivalent molar amount of ramosetron or increased by stress or the like, therefore normalizing the stool other pharmaceutically acceptable salt thereof, and condition to prevent diarrhea (for example, see Non-Patent 0019. 3. The method of 1 or 2 comprising administer References 2 and 3). ing to the patient 1.0 to 5.0 g of polycarbophil calcium as a daily dose or an equivalent molar amount of polycarbophil or PRIOR ART REFERENCES other pharmaceutically acceptable salt thereof. Patent References 0020. The invention also relates to the following: 0005 Patent Reference 1: EP 381422 0021 4Use of ramosetron or a pharmaceutically accept 0006 Patent Reference 2: US 2005/0192329 able salt thereof for the manufacture of a medicament for the US 2011/0158930 A1 Jun. 30, 2011 treatment of irritable bowel syndrome with diarrhea or mixed each group with n=12, in which *P<0.05/3, **P<0.01/3 to irritable bowel syndrome in combination with polycarbophil distilled water administration group (Fisher's exact test). B or a pharmaceutically acceptable salt thereof, and shows the incidence of diarrhea in each group with n=24, in 0022 5. Use of ramosetron hydrochloride in a daily dose which *P<0.05, **P<0.01 to distilled water administration of 0.001 to 0.05 mg, or an equivalent molar amount of ramo group, #P-0.05, #P-0.01 to ramosetron or polycarbophil setron or other pharmaceutically acceptable salt thereof, for administration group (Fisher's exact test).
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar
    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
    [Show full text]
  • MEDEL: Medicare Part D Excluded Drugs
    MEDEL Medicare Part D Excluded Drugs Eligible for Coverage under MEDEL Only drugs provided by MEDEL participating manufacturers will be eligible for coverage. These drugs will maintain the current MEDEL Formulary with enforcement of its existing edits: PDL, Dosage Limitations, etc. Drug Categories / Drug Description Exclusion Cat Drug Categories / Drug Description Exclusion Cat ANALGESICS - MISC. Antidiarrheal Agents - Misc. Salicylates Bismuth Subsalicylate OTC Aspirin OTC Antacids - Aluminum Salts Analgesics Other Aluminum Hydroxide Gel OTC Acetaminophen OTC Antacids - Bicarbonate ANTIASTHMATIC - NASAL MISC. Sodium Bicarbonate (Antacid) OTC Nasal Agents - Misc. Antacids - Calcium Salts Saline OTC ANTICONVULSANTS Calcium Carbonate (Antacid) OTC Anticonvulsants - Benzodiazepines Antacids - Magnesium Salts Clonazepam Benzodiazepines Magnesium Oxide OTC Diazepam (Anticonvulsant) Benzodiazepines Antacid Combinations ANTIHISTAMINES - NON-SEDATING Aluminum & Magnesium Hydroxide OTC Antihistamines - Non-Sedating GI - ANTIPERISTALTIC AGENTS CLARITIN OTC Antiperistaltic Agents loratadine OTC ANXIOLYTICS - BENZODIAZEPINES Loperamide HCl OTC GI - DIGESTIVE ENZYMES Benzodiazepines Digestive Enzymes Alprazolam Benzodiazepines Chlordiazepoxide HCl Benzodiazepines Lactase OTC Clorazepate Dipotassium Benzodiazepines GI - H2-ANTAGONISTS Diazepam Benzodiazepines Lorazepam Benzodiazepines H-2 Antagonists Oxazepam Benzodiazepines Cimetidine OTC COUGH/COLD Famotidine OTC Ranitidine HCl OTC Systemic Decongestants GI - MISC. Pseudoephedrine HCl OTC Saline
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al
    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
    [Show full text]
  • 16.2.5 Compliance And/Or Drug Concentration Data
    Clinical Study Report Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 16.2.5 Compliance and/or Drug Concentration Data Clinical Study Report Confidential Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 Listing 16.2.5-1 Product Dispensation by Subject (Page 1 of 86) Study Population: ITT Subject Amount Dispensed Number Timepoint Study product (logs) R1001 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 4 1.0 g of snus or placebo logs dispensed 0 Week 10 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 4 R1002 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 0 Week 10 0.5 g of snus or placebo logs dispensed 2 1.0 g of snus or placebo logs dispensed 0 R1003 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Clinical Study Report Confidential Covance CRU Study No. 7694-105 Sponsor Protocol No. SM 08-01 Listing 16.2.5-1 Product Dispensation by Subject (Page 2 of 86) Study Population: ITT Subject Amount Dispensed Number Timepoint Study product (logs) R1004 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 3 1.0 g of snus or placebo logs dispensed 3 Week 10 0.5 g of snus or placebo logs dispensed 6 1.0 g of snus or placebo logs dispensed 0 R1005 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Week 6 0.5 g of snus or placebo logs dispensed 4 1.0 g of snus or placebo logs dispensed 2 Week 10 0.5 g of snus or placebo logs dispensed 5 1.0 g of snus or placebo logs dispensed 2 R1006 Week 0 0.5 g of snus or placebo logs dispensed 8 1.0 g of snus or placebo logs dispensed 4 Clinical Study Report Confidential Covance CRU Study No.
    [Show full text]
  • WO 2016/015055 Al 28 January 2016 (28.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/015055 Al 28 January 2016 (28.01.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 38/10 (2006.01) A61P 1/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 38/04 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US20 15/042298 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 27 July 2015 (27.07.2015) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/028,963 25 July 2014 (25.07.2014) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: IRONWOOD PHARMACEUTICALS, INC.
    [Show full text]
  • Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
    (19) TZZ ¥__T (11) EP 2 998 314 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.03.2016 Bulletin 2016/12 C07K 7/08 (2006.01) A61K 38/10 (2006.01) A61K 47/48 (2006.01) A61P 1/00 (2006.01) (21) Application number: 15190713.6 (22) Date of filing: 04.06.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • SHAILUBHAI, Kunwar HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT Audubon, PA 19402 (US) RO SE SI SK TR • JACOB, Gary S. New York, NY 10028 (US) (30) Priority: 04.06.2007 US 933194 P (74) Representative: Cooley (UK) LLP (62) Document number(s) of the earlier application(s) in Dashwood accordance with Art. 76 EPC: 69 Old Broad Street 12162903.4 / 2 527 360 London EC2M 1QS (GB) 08770135.5 / 2 170 930 Remarks: (71) Applicant: Synergy Pharmaceuticals Inc. This application was filed on 21-10-2015 as a New York, NY 10170 (US) divisional application to the application mentioned under INID code 62. (54) AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS (57) The invention provides novel guanylate cycla- esterase. The gastrointestinal disorder may be classified se-C agonist peptides and their use in the treatment of as either irritable bowel syndrome, constipation, or ex- human diseases including gastrointestinal disorders, in- cessive acidity etc. The gastrointestinal disease may be flammation or cancer (e.g., a gastrointestinal cancer).
    [Show full text]
  • Calcium Polycarbophil
    CALCIUM POLYCARBOPHIL- calcium polycarbophil tablet, film coated Cardinal Health Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- 0339-Cardinal Drug Facts Active ingredient (in each caplet) Calcium polycarbophil 625 mg (equivalent to polycarbophil 500 mg) Purpose Bulk-forming laxative Uses relieves occasional constipation (irregularity) generally produces bowel movement in 12 to 72 hours Choking: Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention. Ask a doctor before use if you have abdominal pain, nausea, or vomiting a sudden change in bowel habits that persists over a period of 2 weeks Ask a doctor or pharmacist before use if you are taking any other drug. Take this product two or more hours before or after other drugs. Laxatives may affect how other drugs work. When using this product do not use for more than 7 days unless directed by a doctor do not take more than 8 caplets in a 24-hour period unless directed by a doctor Stop use and ask a doctor if you fail to have a bowel movement after use or have rectal bleeding. These could be signs of a serious condition. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center (1-800-222- 1222) right away.
    [Show full text]
  • Price Master for OCHA File
    Price Master for OCHA File Item Code Item Description Item Price 1210000001 FS-SIXTH SEMI-PRIVATE 2365 1210000006 MED/SUR OVERFLOW SEMI-PVT 2365 1210000007 ED OVERFLOW SEMI-PRIV BED 2365 1210000008 SAME DAY ADMIT SEMI-PRIV BED 2365 1210000009 GS-SEVENTH SEMI-PRIV 1BED 2365 1210000010 ICU-MED/SUR SEMI-PRIV BED 2365 1220000001 OB SEMI-PRIVATE 2420 1230000001 G3 PEDIATRICS SEMI PRIVATE 2150 1240000001 PSYCHIATRIC SEMI PRIVATE 2090 1240000002 ED HOLD PSYCH SEMI PRIVATE 2090 1240000003 SBHU SEMI PRIVATE 2090 1260000001 PSYCH DETOX SEMI PRIVATE 2200 1260000002 ED HOLD PSYCH DETOX SEMI PRIV 2200 1700000002 NURSERY ROOM RATE 1650 2000000001 ICU OVERFLOW PACU 3630 2000000002 INTENSIVE CARE 3630 2060000001 FS ISOLATION 2365 2060000002 FS TELEMETRY BED 2365 2060000003 FS TELEMETRY/ISOLATION 2365 2060000005 GS ISOLATION 2365 2060000006 GS TELEMETRY 2365 2060000007 GS TELEMETRY/ISOLATION 2365 2060000008 ICU ISOLATION 2365 2060000009 ED ISOLATION 2365 2060000010 ED TELEMETRY BED 2365 2060000011 ED TELEMETRY/ISOLATION 2150 2500000001 SODIUM CHLORIDE 0.9% RESP 3 ML NEBULIZATION SOLUTION 1.285 2500000002 ALBUTEROL 1.25 MG/3 ML VIAL.NEB 12.336 2500000003 ALBUTEROL 0.63 MG/3 ML VIAL.NEB 8.523 2500000004 ALBUTEROL/IPRATROPIUM 3 ML INH SOL 2.197 2500000005 RACEPINEPHRINE 2.25% 0.5 ML NEB 14.103 2500000006 ALBUTEROL 5 MG/ML 20 ML NEB SOL 80.6415 2500000007 IPRATROPIUM BROMIDE 0.5 MG/2.5 ML NEB 1.517 2500000009 ALBUTEROL 2.5 MG/3 ML VIAL.NEB 1.533 2500000010 ACETYLCYSTEINE-NONFORMULARY 10% 4 ML VIAL 11.8916 2500000011 TIAGABINE HCL 4 MG TAB 31.496 2500000012
    [Show full text]
  • Bloating Y Distensión Abdominal:¿ Solamente Gas?: Una Mirada Hacia
    Clinical problem Bloating and abdominal distention: Just gas? A look in the direction of physiology David B. Páramo Hernández, MD.1 1 Professor of Clinical Gastroenterology at Santa Clara Abstract Hospital, Clínica Universitaria Universidad de La Sabana, Bogotá Colombia Many patients with functional digestive disorders such as irritable bowel syndrome (IBS) complain of bloating, abdominal distention and similar symptoms. Until recently these symptoms have been poorly understood, Translation from Spanish to English by T.A. Zuur and however new research allows us to clarify some aspects of their pathophysiology. This review discusses The Language Workshop some aspects of these symptoms which are related to intestinal gas and its transit, visceral hypersensitivity, ......................................... viscerosomatic response and to the intestinal microbiota. Received: 02-11-11 Accepted: 22-11-11 Key words Distention, bloating, irritable bowel syndrome (IBS), pathophysiology. INTRODUCTION criteria are based on symptoms. It goes on to say that it is a feeling of abdominal distention which may or may not be Bloating and abdominal distention associated with measurable distention. Th is allows us to infer that the symptom and the sign may be present under Among the various types of functional digestive disorders the same denomination. common discomforts such as bloating and abdominal dis- Now, to perform the offi cial Spanish translation supported tention which are apparently safe can produce signifi cant by the Translations Committ ee of the Rome Foundation, alterations to a patient’s quality of life especially when they the Mexican Gastroenterology magazine translates the are within the framework of conditions such as irritable term “C2: Functional Bloating” as “C2 Infl amación / bowel syndrome (1).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,569,445 B2 Manning Et Al
    USOO6569445B2 (12) United States Patent (10) Patent No.: US 6,569,445 B2 Manning et al. (45) Date of Patent: May 27, 2003 (54) FOOD BARS CONTAINING NUTRITIONAL OTHER PUBLICATIONS SUPPLEMENTS AND ANT-CONSTIPATION AND REGULARITY MANTAINING-AGENTS National Acedemy of Sciences, Subcommittee on Dietary Intake and Nutrient Supplements During Pregnancy, Nutri (75) Inventors: Paul B. Manning, Keswick, VA (US); tion During Pregnancy, p. 240, Washington, D.C. 1990.* Jack H. Schramm, Gordonsville, VA Physician's Desk Reference, 49' Edition, 1995, P 1264 (US); James W. McGrath, Jr., (Medical Economics Data Production Company, Montvale, Keswick, VA (US) New Jersey). (73) Assignee: PBM Pharmaceuticals, Inc., Gordonsville, VA (US) Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (*) Notice: Subject to any disclaimer, the term of this (74) Attorney, Agent, or Firm-Roberta L. Hastreiter; Scott patent is extended or adjusted under 35 B. Feder; Lord, Bissell & Brook U.S.C. 154(b) by 21 days. (57) ABSTRACT (21) Appl. No.: 09/730,194 The present invention provides food bars for consumption (22) Filed: Dec. 5, 2000 by pregnant women, lactating women or women of child e as bearing potential that are attempting to become pregnant (65) Prior Publication Data containing one or more Vitamins and/or minerals, and one or more anti-constipation and regularity-maintaining agents, US 2002/0102330 A1 Aug. 1, 2002 methods for preparing these food bars, and methods for (51) Int. Cl." .......................... A61K 47/00; A23L 1/302 Supplementing the dietary requirements of pregnant Women, (52) U.S. Cl. ............................ 424/439: 426/72; 426/74 lactating Women or Women of childbearing potential that are (58) Field of Search ...........................
    [Show full text]
  • Comparative Efficacy of Linaclotide Versus Other Oral Constipation Treatments in Chronic Constipation: a Network Meta-Analysis
    SN Comprehensive Clinical Medicine (2020) 2:1831–1847 https://doi.org/10.1007/s42399-020-00467-x MEDICINE Comparative Efficacy of Linaclotide Versus Other Oral Constipation Treatments in Chronic Constipation: a Network Meta-analysis Hiroyuki Okumura1 & Wentao Tang2 & Kosuke Iwasaki2 & Shingo Shoji1 & Takeo Odaka3 & Atsushi Nakajima4 Accepted: 18 August 2020 / Published online: 29 August 2020 # The Author(s) 2020 Abstract This systematic literature review and network meta-analysis (NMA) indirectly compared the Japanese standard dose of linaclotide 500 μg with other oral chronic constipation (CC) treatments. PubMed, Cochrane-CENTRAL, Ichushi- Web, and ClinicalTrials.gov were systematically searched for eligible randomized controlledtrialsof43oraldrugs approved globally for CC, including irritable bowel syndrome with constipation (IBS-C) and opioid-induced consti- pation (OIC). The mean difference (95% credible interval) in change from baseline in weekly number of spontane- ous bowel movements (SBM) was compared between linaclotide 500 μg (unapproved in OIC) and other treatments using Bayesian methodology. Fifty-two publications (54 trials) involving 47 treatments (16 drugs, different doses of the same drug treated as different treatments) were included in the NMA. Despite including various drugs/doses, for the mean difference in weekly SBM change, linaclotide 500 μg was statistically significantly more efficacious than other drugs/doses (vs 500 μg linaclotide) including the following: placebo (− 1.907; − 2.568, − 1.237); lubiprostone 16 μg(− 2.090; − 3.226, − 0.968); methylnaltrexone 150 mg (− 1.807; − 3.126, − 0.491), 300 mg (− 1.411; − 2.722, − 0.096), and 450 mg (− 1.405; − 2.708, − 0.097); naloxegol 5 mg (− 2.074; − 4.001, − 0.131) and 12.5 mg (− 1.329; − 2.347, − 0.318); and tegaserod 4 mg (− 1.133; − 2.059, − 0.207) and 12 mg (− 1.024; − 1.822, −0.228), and statistically significantly less effective than linaclotide 600 μg non-approved dose (1.159; 0.123, 2.199) and bisacodyl 10 mg (2.979; 1.723, 4.233).
    [Show full text]